Nanogen/Epoch seal merger deal:
This article was originally published in Clinica
Shareholders of Nanogen and Epoch Biosciences have given the thumbs up to a merger between the two companies. Under the agreement, Epoch stockholders will exchange each share of the Bothell, Washington-based molecular diagnostics firm for 0.4673 Nanogen shares. Based on Nanogen's closing price of $7.27 on December 14 (the day before the announcement), the total value of the transaction is estimated at $97m.